Active, not recruitingNCT06839157
Artificial Intelligence - Assisted Model for Optimal Timing of Surgery in Advanced Ovarian Cancer
Studying OBSOLETE: Primary peritoneal serous/papillary carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Gynecologic Oncology Group
- Enrollment
- 1025 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2016 – 2027
Collaborators
Shanghai Zhongshan Hospital · Sun Yat-Sen University Cancer Center · Fudan University · Zhejiang Cancer Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06839157 on ClinicalTrials.govOther trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06856499Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerUniversity of Colorado, Denver
- RECRUITINGPHASE3NCT06994195A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian CancerSichuan Baili Pharmaceutical Co., Ltd.
- RECRUITINGPHASE2NCT07024784A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesAbbVie
- RECRUITINGNANCT06969833Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube CarcinomaCentre Oscar Lambret
- RECRUITINGPHASE3NCT05659381Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube CancerGOG Foundation
- RECRUITINGNANCT05597683Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal ChemotherapyGangnam Severance Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05456685Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerAbbVie
- RECRUITINGPHASE3NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)Genelux Corporation
See all trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma →